Patient Access 2021

Developments in Strategy for Patient Access

Dr Grace Jennings chaired this opening session introducing a range of experts addressing the following topics: the importance of patient engagement throughout the HTA process, using patient registries in HTAs and future development for patient access in new health technologies.
MAP Patient Access Conference 2021 Session 1: Developments in Strategy for Patient Access

Speakers

Dr Grace Jennings, Associate Director MAP Online, MAP

Grace joined MAP BioPharma as the Head of MAP Online after working at NICE for nine years, most recently as a Senior Scientific Adviser in NICE Scientific Advice. She is passionate about making sure that MAP Online is as useful a resource as possible for members, in order to support the development of and improving patient access to exciting new technologies.

Grace has significant experience in helping both pharma companies and medtech companies, as she was the co-developer of the award-winning META (Medtech Early Technical Assessment) tool. She led the educational programme in NICE Scientific Advice, including the LSE-NICE joint Executive Master’s degree. She also contributed to the Models for the evaluation and purchase of antimicrobials project in collaboration with NHSE.

David Thomas, Co-Chair, Charity Medicines Access Coalition

Experienced government relations, policy and communications professional. Leader with key strengths in collaboration, coaching and supporting the development of individuals. Passionate about having a positive impact on the health of people and communities. Excellent knowledge of NHS and health care policy and in-depth understanding of the workings of government, parliament and policy making process.

Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK

Natalie has been responsible for delivering Genetic Alliance UK’s work in Scotland for the last ten years. Natalie has worked to develop a Virtual Involvement Panel for people living with rare, genetic and undiagnosed conditions in Scotland and is committed to ensuring that their views are at the heart of policy and service development. She has been involved in a number of campaigns, including Genetic Alliance UK’s public petition on access to new medicines for rare diseases in Scotland, and she is particularly passionate about improving access to high-quality information and coordinated care. Natalie provides the role of secretary for the Cross Party Group on Rare, Genetic and Undiagnosed Conditions in the Scottish Parliament and is currently supporting the Scottish Government, as Chair of the Rare Diseases Patient Voices Advisory Group, as they develop the new Scottish Action Plan for Rare Diseases.

She is currently working on a new project ‘Why Medicines Matter’ which seeks to highlight the importance of timely access to new medicines for rare conditions and to consider how Scotland’s new Rare Diseases Action Plan can deliver improved access to services, treatments and drugs.

David Gillen, Global Head Medical Affairs, Menarini Pharma

David is an experienced VP within the biotechnology industry. He is skilled in Oncology, Haematology, and Pharmacovigilance. 

Dr Grace Jennings


Dr Grace Jennings, Associate Director MAP Online, MAP

Grace joined MAP BioPharma as the Head of MAP Online after working at NICE for nine years, most recently as a Senior Scientific Adviser in NICE Scientific Advice. She is passionate about making sure that MAP Online is as useful a resource as possible for members, in order to support the development of and improving patient access to exciting new technologies.

Grace has significant experience of helping both pharma companies and medtech companies, as she was the co-developer of the award-winning META (Medtech Early Technical Assessment) tool. She led on the educational programme in NICE Scientific Advice, including the LSE-NICE joint Executive Master’s degree. She also contributed to the Models for the evaluation and purchase of antimicrobials project in collaboration with NHSE.

David Thomas


David Thomas, Co-Chair, Charity Medicines Access Coalition

[coming soon]

Natalie Frankish


Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK

Natalie has been responsible for delivering Genetic Alliance UK’s work in Scotland for the last ten years. Natalie has worked to develop a Virtual Involvement Panel for people living with rare, genetic and undiagnosed conditions in Scotland and is committed to ensuring that their views are at the heart of policy and service development. She has been involved in a number of campaigns, including Genetic Alliance UK’s public petition on access to new medicines for rare diseases in Scotland, and she is particularly passionate about improving access to high-quality information and coordinated care. Natalie provides the role of secretary for the Cross Party Group on Rare, Genetic and Undiagnosed Conditions in the Scottish Parliament and is currently supporting the Scottish Government, as Chair of the Rare Diseases Patient Voices Advisory Group, as they develop the new Scottish Action Plan for Rare Diseases.

She is currently working on a new project ‘Why Medicines Matter’ which seeks to highlight the importance of timely access to new medicines for rare conditions and to consider how Scotland’s new Rare Diseases Action Plan can deliver improved access to services, treatments and drugs.

David Gillen


David Gillen, Global Head Medical Affairs, Menarini Pharma

David is an experienced VP within the biotechnology industry. He is skilled in Oncology, Haematology, and Pharmacovigilance. 

CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52